AB
Apurva Bhupendra Shah
About Apurva Bhupendra Shah
Data last updated:
Apurva Bhupendra Shah is a Director at Veeda Clinical Research Limited (since 2026), Director at Zetts Cosmetics Private Limited (since 2024) and Director at Jiwa Foods Private Limited (since 2016), and holds 5 more current directorships. The companies operate in Pharma, FMCG and Agriculture. The 5 current companies with reported revenue have a combined latest revenue of ₹843 Cr; the largest is Veeda Clinical Research Limited at ₹621 Cr (FY 2025). Earlier, Apurva Bhupendra Shah was a Director at Tehoco Ventures Private Limited (2024) and Additional Director at Strawberry Polymers Private Limited (2015–2016) and 5 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Veeda Clinical Research Limited U73100GJ2004PLC044023 | Director | 30 Mar 2026 | 2004 | ₹621 Cr (FY 2025) | Active |
 Zetts Cosmetics Private Limited U24246MH2004PTC146152 | Director | 14 Jun 2024 | 2004 | ₹209 Cr (FY 2025) | Active |
 Jiwa Foods Private Limited U15122MH2016PTC272588 | Director | 03 Feb 2016 | 2016 | ₹12.21 Cr (FY 2025) | Active |
 Gsg Pharmaceuticals Private Limited U24290MH2021PTC371034 | Director | 12 Sep 2022 | 2021 | ₹16.5 Lakh (FY 2025) | Active |
| Enzu.Life Private Limited U52390MH2020PTC345635 | Director | 09 Sep 2020 | 2020 | ₹1.6 Lakh (FY 2025) | Active |
| Zylo House Of Brands Private Limited U47722MH2025PTC453349 | Director | 30 Jul 2025 | 2025 | Active | |
| Flint Management Consultants Llp AAV-0852 | Partner | 15 Jan 2021 | 2020 | Active | |
| Saascorp Llp AAT-2137 | Designated Partner | 04 Aug 2020 | 2020 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Tehoco Ventures Private Limited U20234MH2024PTC422649 | Director | 31 May 2024 | 2024 | Amalgamated | |
| Strawberry Polymers Private Limited U25190GJ2014PTC081303 | Additional Director | 21 Jan 2015 | 2014 | ₹10.70 Cr (FY 2019) | Active |
 Alfa Corpuscles Private Limited U29294DL2007PTC163078 | Director | 30 Sep 2014 | 2007 | ₹2.01 Cr (FY 2024) | Active |
| Oshiwara Land Development Private Limited U45200MH1973PTC016274 | Director | 01 Jul 2013 | 1973 | ₹3.6 Lakh (FY 2025) | Converted To Llp |
 Synersoft Technologies Private Limited U72200GJ2008PTC053922 | Additional Director | 03 Apr 2013 | 2008 | ₹10.34 Cr (FY 2025) | Active |
| Point Hospitals Private Limited U85191MH2012PTC232379 | Director | 19 Jun 2012 | 2012 | Active | |
| Shilpveda Infracon Llp AAB-2899 | Designated Partner | 28 Dec 2012 | 2012 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Apurva Bhupendra Shah
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Apurva Bhupendra Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apurva Bhupendra Shah
Apurva Bhupendra Shah currently holds 8 directorships: Veeda Clinical Research Limited (Director, since 30 Mar 2026, revenue ₹621 Cr (FY 2025)); Zetts Cosmetics Private Limited (Director, since 14 Jun 2024, revenue ₹209 Cr (FY 2025)); Jiwa Foods Private Limited (Director, since 03 Feb 2016, revenue ₹12.21 Cr (FY 2025)); Gsg Pharmaceuticals Private Limited (Director, since 12 Sep 2022, revenue ₹16.5 Lakh (FY 2025)); Enzu.Life Private Limited (Director, since 09 Sep 2020, revenue ₹1.6 Lakh (FY 2025)); and 3 more.
Apurva Bhupendra Shah was first appointed on 19 Jun 2012 as Director at Point Hospitals Private Limited. The most recent appointment on record is 30 Mar 2026 at Veeda Clinical Research Limited.
The 5 current companies of Apurva Bhupendra Shah that report revenue have a combined latest revenue of ₹843 Cr: Veeda Clinical Research Limited ₹621 Cr (FY 2025); Zetts Cosmetics Private Limited ₹209 Cr (FY 2025); Jiwa Foods Private Limited ₹12.21 Cr (FY 2025); Gsg Pharmaceuticals Private Limited ₹16.5 Lakh (FY 2025); Enzu.Life Private Limited ₹1.6 Lakh (FY 2025).
Apurva Bhupendra Shah held 7 earlier board appointments: Tehoco Ventures Private Limited (Director, 31 May 2024 to 15 Jul 2024); Strawberry Polymers Private Limited (Additional Director, 21 Jan 2015 to 01 Apr 2016); Alfa Corpuscles Private Limited (Director, 30 Sep 2014 to 27 Oct 2018); Oshiwara Land Development Private Limited (Director, 01 Jul 2013 to 05 May 2014); Synersoft Technologies Private Limited (Additional Director, 03 Apr 2013 to 30 Sep 2013); and 2 more.
The current boards of Apurva Bhupendra Shah's companies include Binoy Hasmukh Gardi (Veeda Clinical Research Limited), Binoy Hasmukh Gardi (Veeda Clinical Research Limited), David Paul Kenny (Veeda Clinical Research Limited), Georgios Kouvatseas (Veeda Clinical Research Limited), Ioannis Orfanidis (Veeda Clinical Research Limited), Jeanne Taylor Hecht (Veeda Clinical Research Limited), among others.